A new paradigm for treating transcription factor-driven cancers

September 18, 2017, Nationwide Children's Hospital
Credit: CC0 Public Domain

In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing sarcoma and how the EWS/FLI transcription factor drives the malignancy – and suggests ways to disrupt the process.

Transcription factors are involved in the process of transcribing DNA into RNA, which is then translated into proteins. The EWS/FLI transcription factor is comprised of two domains, EWS and FLI. The FLI component has a well-defined structure with a surface that fits neatly into a groove in DNA. FLI binds to GGAA-microsatellites responsible for the regulation of many genes required for Ewing sarcoma development, such as the NR0B1 gene.

The presence and location of the GGAA-microsatellites are essential for the development of Ewing sarcoma. If microsatellites are not in the right place in the genome, and of the right sequence and length, it's likely not possible to get this particular type of cancer.

"This knowledge helps to explain some of the questions around susceptibility to Ewing sarcoma," says Stephen Lessnick, MD, PhD, director of the Center for Childhood Cancer and Blood Diseases in The Research Institute at Nationwide Children's and senior author of the study. "For example, Ewing sarcoma is 10 times more prevalent in people of European descent than in people of African descent. Also, humans are the only species that can get Ewing sarcoma. We believe that these patterns are directly related to microsatellite location and length. There appears to be a 'sweet-spot' microsatellite length where EWS/FLI is most effective at regulating gene expression."

The FLI subunit binds to GGAA-microsatellites, and it had been thought that the EWS portion regulates gene expression. However, the Lessnick team found that EWS also works with the FLI portion to help it bind GGAA-microsatellites of "sweet-spot" length. But how does EWS do this? According to Dr. Lessnick, this is one puzzle that the team is working to solve. One of the pieces of the puzzle is that EWS lacks a rigid structure. In fact, Dr. Lessnick says its structure is more akin a strand of spaghetti.

Traditional cancer therapies are built on the lock and key construct. Enzymes have pockets that can be filled with a drug to block their function. Cells have receptors that can be blocked with a drug. With the EWS, there's no rigid structure, and therefore no apparent "lock" for the "key" to target.

"The theory is that the EWS component is interacting and communicating with FLI, helping it to bind DNA, and at the same time is interfacing with other cellular proteins to turn on that causes Ewing sarcoma," says Dr. Lessnick, who is also professor of Pediatrics at The Ohio State University College of Medicine. "The EWS portion may be locking together in some way or segregating cellular components to create neighborhoods – more work needs to be done to determine the mechanism."

Figuring out how EWS interacts with other EWS portions, and with FLI, could result in a clinical revolution for transcription factor-driven cancers. "If you can disrupt the function of the EWS component, you can stop cancer in its tracks. New cancer would be prevented, and the that exists will die," says Dr. Lessnick. "Another target would be to block the binding of FLI to the microsatellites. Without this binding, Ewing sarcoma can't manifest."

Further research is still needed to bring applications of this discovery to the clinic, but the implications of understanding the interactions between and microsatellites extends beyond Ewing . "Other transcription factor driven cancers, and even potentially Alzheimer's disease, may have new treatments as we continue to learn more about these processes," Dr. Lessnick says. "As our understanding grows, it is exciting to consider the future of this area of research."

Explore further: Possible new treatment for Ewing sarcoma

More information: Kirsten M. Johnson et al. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1701872114

Related Stories

Possible new treatment for Ewing sarcoma

November 26, 2012
Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults, and the previously unknown mechanism behind it, come hand-in-hand in a new study by researchers from ...

A noncoding RNA promotes pediatric bone cancer

November 17, 2014
Ewing sarcoma is a cancer of bone or its surrounding soft tissue that primarily affects children and young adults. A hallmark of Ewing sarcoma is a translocation event that results in the fusion of an RNA binding protein, ...

New compounds may aid in development of targeted therapies for a rare pediatric cancer

March 30, 2016
Two recently discovered compounds have shown promise in preclinical studies for treating Ewing sarcoma, a rare cancer that predominantly affects children and adolescents.

Epigenetic diversity in childhood cancer

January 30, 2017
Tumors of the elderly, such as breast cancer and colon cancer, accumulate thousands of DNA mutations. These genetic defects contribute to cancer-specific properties including uncontrolled growth, invasion in neighboring tissues, ...

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017
By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.